Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Study Group: Solexa Genome Analysis System Users(?)

Council Members in this Study Group: 40

This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.

Request a survey with this Study Group







Leading Experts in this Study Group

Gregory Khitrov, PhD, Director of Personalized Medicine Program, MOUNT SINAI SCHOOL OF MEDICINE Gregory Khitrov, PhD
Director of Personalized Medicine Program
MOUNT SINAI SCHOOL OF MEDICINE

Greg Khitrov, PhD, is the Director of Life Sciences Technology Center at the Institute for Personalized Medicine, Director of Biobank and an Assistant Professor of Medicine at the Mount Sinai School of Medicine in New York. He has expertise in molecular biology; proteomics; and laboratory automation...

GLG NewsSMAnalyses by this Study Group's Leading Experts(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
1000 genomes - personalized medicine on sight | 01-25-2008
Author: GLG Expert Contributor

This is a major project that will change teh way we view genome analysis and personalized medicine. For the first time, we will have almost complete information on the DNA sequence of more than 1000 individuals. It will allow the development of methodologies to generate data and interpret genetic information. There...

MRSA kills more Americans annually than HIV | 10-22-2007
Analysis of: Drug-Resistant Staph Germ's Toll Is Higher Than Thought | www.washingtonpost.com
Author: GLG Expert Contributor

* MRSA is a serious problem in the US, particularly with the increasing spread of community acquired strains (caMRSA). * Toxins produced by many caMRSA are rapidly lethal in populations who get soft-tissue infections or sepsis from these organisms (children, elderly). * Nosocomically-acquired MRSAs...

Another HIV-VL assay from a company plagued with recalls | 09-27-2007
Author: GLG Expert Contributor

* Another HIV viral load assay in an increasingly crowded market. * Abbott has a reputation for recalls and recalcitrance in its diagnostics arena. 2007 has not been a good year for them. * Not clear this assay provides significant advantages over other assays recently obtaining FDA approval.

Stregnths and weaknesses of daptomycin use for MRSA infections | 09-24-2007
Author: GLG Expert Contributor

* New class of antibiotic with activity against MRSA that has been used in the US to treat sepsis and severe infections. * As or more expensive than other drug regimens for the patient populations indicated. * Resistance to daptomycin has been reported in MRSA and enterococci. * Has a role, but generally...

Interesting peptide antibiotic with cidal activity, but potential toxic side effects on eukaryotic cells in vitro | 09-24-2007
Author: GLG Expert Contributor

* Some interesting in vitro data regarding cidal/killing activity of oritavancin, another peptide antibiotic in the same class as vancomycin. * No significant animal models to date. * One study has shown some toxic effects on eukaryotic cells in vitro. * Remains to be determined if this antibiotic...

View All GLG News by members of this Study Group

GLG InstituteSM Seminars with this Study Group's Leading Experts(?)

 

Recent Seminars

GLGi: Genotyping Technologies
New York, 04-26-2007

Most Common Company Types:

  • Academic Institution*
  • Academic Medical Center/Hospital or Clinic
  • Research Foundation
  • Biotechnology Manufacturer

Most Common Job Types:

  • Director
  • Professor
  • Research Scientist
  • Researcher
  • Physician - Department Chair
  • Physician - Director
  • Project Manager
  • Physician - Attending Physician
  • Assistant Professor

GLG's 750+ Clients Include:

40 of the leading 50
global mutual funds
15 of the leading 20
global banks
8 of the leading 10
private equity firms
90%+ client subscription renewal rate

Analytics


Generated at 2008-12-05T01:45:24.617